1. Home
  2. CRTO vs MPLT Comparison

CRTO vs MPLT Comparison

Compare CRTO & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$17.80

Market Cap

980.6M

ML Signal

HOLD

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$17.27

Market Cap

811.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRTO
MPLT
Founded
2005
2018
Country
France
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.6M
811.3M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
CRTO
MPLT
Price
$17.80
$17.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
4
Target Price
$35.90
$31.00
AVG Volume (30 Days)
502.7K
144.3K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
38.95
N/A
EPS
2.64
N/A
Revenue
$2,296,692,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.20
N/A
P/E Ratio
$6.75
N/A
Revenue Growth
27.65
N/A
52 Week Low
$16.15
$12.24
52 Week High
$38.97
$21.55

Technical Indicators

Market Signals
Indicator
CRTO
MPLT
Relative Strength Index (RSI) 46.91 47.17
Support Level $17.83 $16.06
Resistance Level $21.32 $20.20
Average True Range (ATR) 1.05 1.19
MACD 0.08 -0.01
Stochastic Oscillator 55.34 19.19

Price Performance

Historical Comparison
CRTO
MPLT

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

Share on Social Networks: